Log in to save to my catalogue

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2516842414

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Patients with metastatic triple-negative breast cancer were treated with standard chemotherapy or the anti–Trop-2 antibody–drug conjugate sacituzumab govitecan. Patients receiving the drug conjugate had significantly longer progression-free and overall survival as well as more frequent myelotoxic effects and diarrhea.

Alternative Titles

Full title

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2516842414

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2516842414

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2028485

How to access this item